Sunil Healthcare Valuation

Is 537253 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 537253 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 537253's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 537253's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 537253?

Key metric: As 537253 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 537253. This is calculated by dividing 537253's market cap by their current revenue.
What is 537253's PS Ratio?
PS Ratio	0.9x
Sales	₹857.34m
Market Cap	₹769.00m

537253 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.6x
Enterprise Value/EBITDA	21.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 537253's PS Ratio compare to its peers?

The above table shows the PS ratio for 537253 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.9x
506919 Makers Laboratories	0.9x	n/a	₹972.7m
530317 Godavari Drugs	0.6x	n/a	₹862.2m
524790 Everest Organics	0.6x	n/a	₹1.1b
543963 Shelter Pharma	1.4x	n/a	₹613.6m
537253 Sunil Healthcare	0.9x	n/a	₹769.0m

Price-To-Sales vs Peers: 537253 is expensive based on its Price-To-Sales Ratio (0.9x) compared to the peer average (0.9x).

Price to Sales Ratio vs Industry

How does 537253's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

14 Companies	Price / Sales	Estimated Growth	Market Cap
NECLIFE Nectar Lifesciences	0.5x	n/a	US$89.21m
539561 Remedium Lifecare	0.07x	n/a	US$28.41m
532637 Mangalam Drugs & Organics	0.5x	n/a	US$20.04m
524412 Aarey Drugs & Pharmaceuticals	0.3x	n/a	US$19.22m

14 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 537253 is good value based on its Price-To-Sales Ratio (0.9x) compared to the Indian Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is 537253's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

537253 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 537253's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vilin Bio Med

₹293.6m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹21.05

7.4%

-0.9%

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹291.85

-3.6%

-22.2%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

-1.7%

15.6%